Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH).
Journal of Clinical Oncology.
Times cited: 134
Scientific advances in lung cancer 2015.
Journal of Thoracic Oncology.
Times cited: 112
Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network.
Times cited: 2030